May 2021 updates to the website

The website has now been updated following May's LSCMMG

The following guidelines have been added/updated:

Erectile Dysfunction Guideline - Updated

The following medicines have been updated:

Liothyronine - For the management of chronic hypothyroidism in primary care - Updated

Liothyronine - Add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine in primary care - Updated

Liothyronine - For the treatment of acute conditions where thyroid replacement is needed rapidly, for a limited period and/or where a drug with shorter half-life is required - Updated

Thyroid extracts (Unlicensed liothyronine and thyroid extract products) - Hypothyroidism - Updated

Liothyronine - Liothyronine therapy commenced in the private sector - Updated

The following Items will be updated and added to the website following the next Joint Committee of CCGs (JCCCG) Meeting:

Bempedoic acid with ezetimibe (NICE TA694) - for treating primary hypercholesterolaemia or mixed dyslipidaemia

Ketamine (Parenteral use) - Chronic Non-Cancer Pain (off-label use) in adults 

iIsulin lispro (Lyumjev) - Treatment of diabetes mellitus in adults

Liothyronine - Add-on treatment for refractory hypothyroidism in secondary care – existing patients

Liothronine - Add-on treatment for refractory hypothyroidism in secondary care – new patients

Liothyronine - Liothyronine monotherapy for the management of chronic hypothyroidism – secondary care